北京植德律师事务所 关于 江西富祥药业股份有限公司 第一期员工持股计划终止相关事宜的 法律意见书 Merits & Tree Law Offices 北京市东城区东直门南大街 1 号来福士中心办公楼 5 层 邮编：100007 5 th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel)：010-56500900 传真(Fax)：010-56500999 www.meritsandtree.com 植德(证)字[2023]046-1 号 二〇二三年九月 北京植德律师事务所 北京植德律师事务所 关于江西富祥药业股份有限公司 第一期员工持股计划终止相关事宜的 法律意见书 植德(证)字[2023]046-1 号 致：江西富祥药业股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、中国证券监督管理委员会（以下简称"中国 证监会"）发布的《关于上市公司实施员工持 ...

根据《中华人民共和国公司法》《中华人民共和国证券法》《关于上市公司实施员 工持股计划试点的指导意见》《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》及《江西富祥药业股份有限公司第一期员工持股计划（草案）》 等有关规定，同意终止实施公司第一期员工持股计划。具体内容详见巨潮资讯网 （http://www.cninfo.com.cn）。 董事喻文军先生、程荣武先生为本次员工持股计划的参与对象，系关联董事，已 回避表决，其他非关联董事参与本议案的表决。 证券代码：300497 证券简称：富祥药业 公告编号：2023-080 江西富祥药业股份有限公司 第四届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司（以下简称"公司"）第四届董事会第十三次会议于 2023 年 9 月 13 日以电子邮件等方式通知全体董事，并于 2023 年 9 月 15 日以现场及 通讯的方式举行。会议应出席董事 8 人，实际出席的董事 8 人。会议由董事长包建华 主持。会议召开和表决程序符合《中华人民共和国公司法》等 ...

第一期员工持股计划第三次持有人会议决议公告 证券代码：300497 证券简称：富祥药业 公告编号：2023-076 江西富祥药业股份有限公司 表决结果：同意6,434,026份，占出席持有人会议的持有人所持份额总数的100%； 反对0份；弃权0份。 特此公告。 江西富祥药业股份有限公司 董事会 2023 年 9 月 15 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司（以下简称"公司"）第一期员工持股计划第三次持 有人会议于 2023 年 9 月 11 日以书面、电子邮件、短信、电话等方式通知全体持有人， 并于 2023 年 9 月 14 日以现场及通讯的方式举行。本次会议由员工持股计划管理委员 会主任胥文先生主持，出席本次持有人会议的持有人共 24 人，共代表本次员工持股 计划份额 6,434,026 份，占本次员工持股计划份额总数的 56.67%。本次会议审议通过 了以下决议： 一、审议通过《关于终止实施第一期员工持股计划的议案》 根据《中华人民共和国公司法》《中华人民共和国证券法》《关于上市公司实施员 工持股计划试点的指导意 ...

长江证券承销保荐有限公司 关于江西富祥药业股份有限公司 2023 年半年度持续督导跟踪报告 保荐机构名称：长江证券承销保荐有限公司 被保荐公司简称：富祥药业 保荐代表人姓名：王海涛 联系电话：010-57065285 保荐代表人姓名：梁国超 联系电话：010-57065382 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2．督导公司建立健全并有效执行规章制度 | | | 的情况 | | | （1）是否督导公司建立健全规章制度（包 括但不限于防止关联方占用公司资源的制 | 是 | | 度、募集资金管理制度、内控制度、内部审 | | | 计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 1 次 | | （2）公司募集资金项目进展是否与信息披 | 是 | | 露文件一致 | | | 4.公司治理督导情况 | | | （1）列席公 ...

| 1.是否在募集资金到位后一个月内签订三方监管协议 | √ | | | | --- | --- | --- | --- | | 2.募集资金三方监管协议是否有效执行 | √ | | | | 3.募集资金是否不存在第三方占用或违规进行委托理财等情形 | √ | | | | 4.是否不存在未履行审议程序擅自变更募集资金用途、暂时补充流 | √ | | | | 动资金、置换预先投入、改变实施地点等情形 | | | | | 5.使用闲置募集资金暂时补充流动资金、将募集资金投向变更为永 | | | | | 久性补充流动资金或者使用超募资金补充流动资金或者偿还银行 √ | | | | | 贷款的，公司是否未在承诺期间进行风险投资 | | | | | 6.募集资金使用与已披露情况是否一致，项目进度、投资效益是否 | √ | | | | 与招股说明书等相符 | | | | | 7.募集资金项目实施过程中是否不存在重大风险 | √ | | | | （六）业绩情况 | 是 | 否 | 不适用 | | 现场检查手段： | | | | | （1）核查公司披露的定期报告及业绩预告文件，了解业绩波动情况；（2）对有关文件、原 | | ...

证券代码：300497 证券简称：富祥药业 公告编号：2023-075 江西富祥药业股份有限公司 关于公司副总经理增持完成的公告 公司副总经理陈应惠先生保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 江西富祥药业股份有限公司（以下简称"公司"）于2023年6月19日在巨潮资讯 网上披露了《关于公司副董事长及副总经理增持公司股份计划的公告》（公告编号： 2023-054），公司副总经理陈应惠先生基于对公司未来发展的信心以及对公司价值的 认可，计划自上述公告之日起6个月内通过集中竞价方式增持公司股份，增持金额不 低于80万元且不超过120万元。 近日，公司收到副总经理陈应惠先生的通知，获悉其增持公司股份已实施完毕， 现将有关情况公告如下： 一、本次增持计划的完成情况 截至本公告日，陈应惠先生通过集中竞价方式增持公司股份85,000股，增持金额 977,500元人民币，本次增持计划已实施完成。增持计划完成具体情况如下： | 股东名称 | 增持方式 | 增持期间 | 增持均价 | 增持股数 | 增持金额 | 占剔除 ...

证券代码：300497 证券简称：富祥药业 公告编号：2023-074 4、住所：浙江省台州市黄岩区头陀镇镇西村 5、法定代表人：林佳芝 6、注册资本：壹仟万元整 7、成立日期：2018年08月02日 江西富祥药业股份有限公司 关于全资子公司完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司全资子公司富祥（台州）生命科学有限公司于近日办 理了注册地址工商变更登记手续，现已取得台州市黄岩区市场监督管理局换发的《营 业执照》，登记的相关信息如下： 1、统一社会信用代码：91331003MA2ANRFB41 2、企业名称：富祥（台州）生命科学有限公司 3、类型：有限责任公司（非自然人投资或控股的法人独资） 董事会 2023 年 9 月 5 日 8、经营范围：生命科学仪器研发，医学研究和试验发展，医药原料及中间体、 生物化学制品（不含危险化学品及易制毒化学品）研发、销售，新药技术开发，技术 进出口与货物进出口。（依法须经批准的项目，经相关部门批准后方可开展经营活动） 特此公告。 江西富祥药业股份有限公司 ...

证券代码：300497 证券简称：富祥药业 公告编号：2023-073 江西富祥药业股份有限公司 关于公司副董事长增持完成的公告 公司副董事长李惠跃先生保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 注：本公告中合计数与各分项数据之和的尾数差异，为四舍五入所致。 三、其他说明 1、本次增持不会导致股数股权分布不符合上市条件，不会导致公司控制权发生 变化； 2、本次增持计划符合《公司法》《证券法》《深圳证券交易所创业板股票上市 规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》 等法律、法规、规范性文件的有关规定。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 江西富祥药业股份有限公司（以下简称"公司"）于2023年6月19日在巨潮资讯 网上披露了《关于公司副董事长及副总经理增持公司股份计划的公告》（公告编号： 2023-054），公司副董事长李惠跃先生基于对公司未来发展的信心以及对公司价值的 认可，计划自上述公告之日起6个月内通过集中竞价方式增持公司股份，增持金额不 低于150万元且不超过250万元。 近日，公司收到副董事长李 ...

Sustainable Development and Environmental Management - The company reported a focus on developing a sustainable product portfolio, including chemical synthesis enzyme inhibitors and sterile raw materials, to ensure future growth capabilities[8]. - The company has committed to increasing its investment in environmental protection and management to comply with stricter national standards[10]. - The company is committed to maintaining a rigorous approach to environmental management and compliance with safety regulations[10]. - Environmental protection measures have been prioritized, with an increase in investment for pollution control by 30% over the past year[115]. - The company has enhanced its wastewater treatment capacity, with a daily processing capacity of 2,000 tons for wastewater biological treatment[135]. - The company has introduced advanced recovery devices to reduce hazardous waste generation and ensures compliance with hazardous waste management regulations[136]. - The company has installed waste gas absorption devices and an environmentally friendly vacuum system in its production workshops[135]. - The company has conducted clean production audits to effectively implement deep recovery and comprehensive utilization of process wastewater[135]. - The company has adopted a closed production system to strengthen the control of unorganized waste gas emissions[135]. - The company invested approximately RMB 18.04 million in new environmental protection facilities during the reporting period[137]. - Environmental operation expenses amounted to about RMB 30.45 million, with environmental protection tax paid of approximately RMB 48,500[137]. - The company has implemented three types of monitoring measures for pollutant emissions, including online monitoring systems for exhaust and wastewater[139]. - The company received an administrative penalty of RMB 127,343 for violating water pollution prevention laws, but it did not significantly impact operations[138]. - The company has a total of 84 environmental protection personnel, including 10 qualified testing personnel, to monitor environmental compliance[136]. Financial Performance and Revenue Growth - Jiangxi Fushine Pharmaceutical Co., Ltd. reported a significant increase in revenue for the first half of 2023, reaching RMB 500 million, representing a 20% year-over-year growth[28]. - The company achieved a gross profit margin of 45% in the first half of 2023, compared to 40% in the same period last year, indicating improved operational efficiency[29]. - The company reported a net profit of RMB 150 million for the first half of 2023, up 30% from the previous year, showcasing strong financial performance[29]. - Future guidance indicates a projected revenue growth of 25% for the full year 2023, driven by new product launches and market expansion efforts[28]. - The company reported a total revenue of 89,000 million CNY for the first half of 2023, representing a 68.01% increase compared to the same period last year[103]. - The company reported a total operating revenue of 2022 at 9.9 million, with specific details on revenue and deductions provided in the supplementary announcement[167]. - The company expects operating revenue for the first half of 2023 to be between RMB 155 million and RMB 170 million, with a net revenue after deductions projected between RMB 150 million and RMB 165 million[168]. Research and Development Initiatives - The company plans to enhance its research and development capabilities to meet the high demands of new product development and industrialization[12]. - The company is investing RMB 50 million in R&D for new technologies aimed at enhancing the efficacy of its antibiotic products[29]. - The company has established a new research institute in March 2023, enhancing its R&D capabilities and focusing on process optimization and technological innovation[64]. - The company is actively developing microbial protein, aligning with national food security strategies and sustainable development goals[69]. - The company plans to increase R&D investment while conducting thorough market research to mitigate risks associated with drug development cycles and market changes[116]. - The company has completed pilot tests for several new products, including Thienamycin and HMDS, which are expected to enrich the product line and enhance core competitiveness[66]. Market Expansion and Competitive Strategy - The company is actively expanding its international market presence, with foreign sales accounting for a stable proportion of total revenue[11]. - The company is optimistic about the prospects of new energy materials and plans to continuously innovate and adjust product structures in response to market conditions[9]. - Jiangxi Fushine's market expansion strategy includes entering two new international markets by the end of 2023, targeting a 10% increase in export sales[28]. - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products and technologies were not detailed in the report[200]. - The company aims to enhance its competitive edge by implementing cost reduction and efficiency improvement measures, while also expanding its product industry chain to mitigate systemic risks[9]. - The company is focusing on expanding its market presence in the lithium battery electrolyte additive sector, targeting a 15% market share by 2025[114]. Risk Management and Compliance - The company acknowledges the risk of raw material price fluctuations, which significantly impact its production costs, and plans to stabilize procurement prices through strategic partnerships[14]. - The company emphasizes the importance of thorough market research and feasibility analysis for its investment projects to mitigate potential risks[15]. - The company is monitoring raw material prices and optimizing production processes to mitigate the impact of high costs on profit margins[66]. - The company has conducted comprehensive feasibility studies for its investment projects, but acknowledges risks related to market environment changes and policy shifts[117]. - The company is committed to maintaining deep cooperation with upstream suppliers to manage raw material costs effectively[116]. Corporate Governance and Shareholder Relations - The company has enhanced its governance structure in accordance with relevant laws and regulations, promoting effective internal controls[140]. - The company maintains a strong focus on investor relations, ensuring timely and accurate information disclosure to protect investor rights[141]. - The company has implemented measures to recover unachieved performance indicators related to its employee stock ownership plan[126]. - The company has committed to strictly adhere to the stock lock-up commitments disclosed in the IPO prospectus, with the lock-up period starting from December 22, 2015[144]. - The company will announce any share reduction three trading days in advance and fulfill information disclosure obligations in a timely and accurate manner[144]. - The company has a management agreement with Zhejiang Bangfu Biological Technology Co., Ltd., with an annual management fee of 1 million RMB for a period of three years[159]. Operational Challenges and Financial Adjustments - The company reported a net cash flow from operating activities was a negative ¥83.59 million, representing a decline of 703.24% compared to a negative cash flow of ¥10.41 million in the previous year[37]. - The company has experienced changes in its board and management, with new appointments made to align with strategic needs[122]. - The company is facing delays in certain fundraising projects due to uncontrollable factors, affecting the timeline for the "Fuxiang Biopharmaceutical Project" and the "Annual Production of 10,000 Tons of VC and 2,000 Tons of FEC Project"[168]. - The company is conducting impairment tests on inventory and analyzing investment-related losses due to changing market conditions, leading to additional provisions for inventory impairment[168]. - The company has proposed to increase the number of board members from 7 to 8, with the number of non-independent directors increasing from 4 to 5[168].

江西富祥药业股份有限公司（以下简称"公司"）于2023年4月26日在巨潮资讯 网（http://www.cninfo.com.cn）上披露了《关于持股5%以上股东股份减持计划的提示 性公告》（公告编号：2023-045）。 2023年8月29日接到公司控股股东包建华先生通知，提前终止本次减持计划。 特此公告。 江西富祥药业股份有限公司 董事会 2023 年 8 月 29 日 证券代码：300497 证券简称：富祥药业 公告编号：2023-067 江西富祥药业股份有限公司 关于控股股东提前终止减持计划的公告 持股5%以上的控股股东包建华先生保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 ...